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Diarylethene moiety as an enthalpy-entropy
switch: photoisomerizable stapled peptides for
modulating p53/MDM2 interaction†
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Teodors Pantelejevs,d Wenshu Xu,a Elaine Fowler, a Rohan Eapen, e
Krishna Sharma, a Maxim O. Platonov, b Vasyl V. Hurmach,b,f Laura Itzhaki,e
Marko Hyvönen, d Anne S. Ulrich, *c,g David R. Spring *a and
Igor V. Komarov *f,h
Analogs of the known inhibitor (peptide pDI) of the p53/MDM2 protein–protein interaction are reported,
which are stapled by linkers bearing a photoisomerizable diarylethene moiety. The corresponding photoi-
somers possess significantly different affinities to the p53-interacting domain of the human MDM2.
Apparent dissociation constants are in the picomolar-to-low nanomolar range for those isomers with dia-
rylethene in the “open” configuration, but up to eight times larger for the corresponding “closed” isomers.
Spectroscopic, structural, and computational studies showed that the stapling linkers of the peptides con-
tribute to their binding. Calorimetry revealed that the binding of the “closed” isomers is mostly enthalpy-
driven, whereas the “open” photoforms bind to the protein stronger due to their increased binding
entropy. The results suggest that conformational dynamics of the protein-peptide complexes may explain
the differences in the thermodynamic profiles of the binding.
Introduction
Reversibly photoisomerizable (i.e. “photoswitchable”) bioactive
compounds and molecular systems are the subjects of intense
research in the recent decade.1 Half a century after photoregu-
lation of the biological activity of an azobenzene derivative was
first reported,2 translational researches seem to be close to real
applications of the photoswitchable compounds in pharma-
cology.3 The term “photopharmacology” has even been
coined4 for the medicinal use of such compounds, although
there are no approved photoswitchable drugs available yet.5 A
driving force for research toward their medicinal applications
is the general belief that the safety of drugs can be improved
by exerting spatiotemporal control over their activity using
light. Indeed, the safety advantage at the efficacy doses for
some representative photoswitchable drug candidates has
already been convincingly demonstrated in proof-of-principle
studies in vivo.6
Most of the reported photoswitchable biologically active
compounds are small molecules that exploit photoisomeriza-
tion of azobenzene building blocks.1,7 Due to the significant
structural change of the cis- or trans-azobenzene unit upon iso-
merization, the photoisomers of azobenzene derivatives differ
significantly in geometry, which can, therefore, substantially
affect their biological activity.8 Extensive research has been
directed to overcoming two major drawbacks of these azo-
benzene-based biologically active compounds, namely (i) the
high rate of in vivo reduction of the azo group, and (ii) the
intrinsic thermal instability of the cis-photo-forms.7c At the
same time, it is known that photoisomerizable compounds of
another type, the diarylethene (DAE) derivatives (Fig. 1), are
reasonably inert in vivo and thermally stable in their both
photoforms.9 The photochromism and thermal stability of dia-
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rylethenes have been known for almost thirty years.10 However,
until the last decade, no reports on the photocontrolled bio-
logically active DAE-based compounds were published. It has
been suggested11 that the evidently small structural changes
upon photoisomerization12 may have discouraged an active
search for biologically active photoswitchable DAE derivatives.
In 2012, α-helical DNA-binding peptides were described,
cross-linked by a DAE-derived bridge between two non-neigh-
bouring side chains. In these constructs, both helicity and
DNA binding affinity varied reversibly upon photoisomeriza-
tion.13 This study demonstrated for the first time that struc-
tural contexts – where DAE photoisomerization should lead to
considerable changes in binding affinity to a target – can be
found in polypeptides. Further studies demonstrated appreci-
able effects of DAE photoisomerization in other types of
peptide structure, such as a cyclic β-hairpin14 and a helix-
hinge-helix motif.15
Two recent works, on a small-molecule DAE-containing
inhibitor of phosphoribosyl isomerase A from Mycobacterium
tuberculosis,16 and on a similarly designed protein kinase C
inhibitor,17 pointed to an essential DAE property that is impor-
tant for the efficiency of photocontrol, namely, the differential
rigidity/flexibility of the two DAE photoforms (Fig. 1). Those
derivatives bearing a flexible (“open”) DAE unit can adapt their
conformation to the binding target and tend to show higher
inhibitory activity than the rigid (“closed”) photoisomers. We
reasoned that this characteristic property of the DAE moiety
could be usefully applied to design photoswitchable inhibitors
of protein–protein interactions (PPIs).11
PPIs are the key players in signal transduction and regulat-
ory cascades in every living cell; therefore, disease-associated
PPIs are regarded as important targets in drug discovery.18 It
has been observed that conformationally flexible mediators of
PPIs often show higher inhibitory capacity than their rigid
counterparts.19 Addition of constrains to the ligands, on the
contrary, can lead to less favourable changes in binding
entropy.20 These findings suggest that light-induced changes
in the conformational flexibility/rigidity of DAE-derived PPI
modulators could provide an effective means for controlling
their inhibitory efficiency.
Here, we provide evidence for the validity of this hypothesis,
based on our research of DAE-derived photocontrolled pep-
tides that are capable of inhibiting the interaction between
p53 and the E3 ubiquitin ligase murine double minute
2 homolog (MDM2). This interaction is a part of a complex
interplay between the tumour suppressor protein p53 and its
two natural inhibitors (oncogenic proteins MDM2 and
MDMX), and is regarded as an important target for anticancer
therapeutics.21 p53/MDM2/X PPI is one of the best-studied and
most targeted intracellular PPIs related to cancer progression.
Several compounds that disrupt the p53/MDM2/X interaction
are under clinical trials, including peptides.22 The dual pepti-
dic MDM2/MDMX antagonist ALRN-6924 was the first stapled
helical peptide to enter clinical trials23 (now in Phase I/II24).
Nevertheless, the toxicity associated with p53 activation has
been reported as a critical issue on the way toward clinical
application of the MDM2/MDMX antagonists.21b This fact
encouraged us to develop photoswitchable p53/MDM2 antag-
onists, possibly having an improved safety profile.
In the present study, we report on a series of compounds
which demonstrate efficient photocontrol of binding to the
p53-interacting domain of the human MDM2, with Ki in the
picomolar-to-submicromolar range. To the best of our knowl-
edge, these are the first examples of DAE-containing peptidic
PPI modulators. These new photocontrollable compounds
complement the repertoire of the azobenzene-stapled PPI
inhibitors which have been described in the literature, e.g.
against the Bak(Bid)/Bcl-x(L) interaction (involved in the regu-
lation of the programmed cell death),25 β-arrestin/β2-adaptin
PPI (involved in the regulation of clathrin-mediated
endocytosis),19c,26 and the WDR5–MLL1 interaction27 (involved
in transcriptional regulation and leukemogenesis).
Results and discussion
Compound design
We have used peptidic templates for the design of our MDM2
antagonists first of all because peptides were shown to be
highly efficient modulators of PPIs.28 As the medium-sized
peptide molecules (10–12 amino acid residues) are much
larger than the DAE moiety, incorporation of this photoswitch
should not disturb the peptide pharmacophores too much, at
least compared to small-molecule templates. This feature pro-
vides numerous options for varying the position of the DAE
fragment, and, correspondingly, allows for optimizing the
control of the biological activity by light. It has also been
shown that cyclic peptides can serve as a convenient platform
for molecular grafting, such as to mimic functional motifs of
biologically active proteins,29 and they are usually more meta-
bolically stable compared to their linear analogues.22b
We considered two general design strategies for our mole-
cules, schematically illustrated in Fig. 2. In one strategy, the
residues at the PPI interface that are critical for the interaction
are grafted onto a cyclic β-hairpin scaffold, equipped with a
DAE moiety at one of the turn positions. The other strategy
uses an α-helix scaffold, stabilized by cross-linking (DAE-sta-
pling) of two appropriate amino acid side chains. We have
recently demonstrated the utility of β-hairpin scaffolds in the
development of photoswitchable membranolytic peptides.6a,14
Fig. 1 Photoisomerizable DAE moiety (X = S, NH, O), illustrating the
nomenclature of the photoisomers used in this work, and characteristic
changes in the molecular flexibility associated with photoisomerization.
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In the present work, we thus followed the second strategy,
exploring the α-helical DAE-stapled peptide geometry. Our
choice has been stimulated by the fact that many known
efficient PPI modulators are stapled helical peptides.22a The
amino acid sequences of these peptides are usually derived
from the protein interaction surfaces, which often contain
specific α-helical regions.30 The modular design of stapled
peptides allows for the straightforward incorporation of a
photoisomerizable moiety, as was shown earlier for the azo-
benzene-stapled PPI inhibitors.25a,31
The known stapled helical peptides reported as efficient p53/
MDM2/X interaction inhibitors32 have usually been derived
from linear sequences discovered by phage display. One such
sequence, the pDI (Ac-LTFEHYWAQLTS-NH2), was reported in
2007.33 This peptide and its derivatives were proven to be very
potent MDM2 antagonists. Hence, we decided to use the pDI as
an initial peptide template for our design.
It is known from X-ray34 and computational35 studies that
p53 binds to MDM2 with an essential contribution from three
residues within the so-called “p53 hot spot”: Phe, Trp, and Leu
located on the α-helical frame of the p53 N-terminal domain.
Therefore, these residues and their spatial positions should be
retained in the analogues. In ref. 32d, the authors used a pDI-
derived sequence 1a (Fig. 3a, Ac-LTF-(Orn(N3))-EYWAQL-(Orn
(N3))-S-NH2; Orn(N3): L-azidoornithine) to prepare the stapled
p53/MDM2 interaction inhibitors using the azide–alkyne cyclo-
addition (“click”) reaction. The Orn(N3) residues occupy the (i,
i + 7) positions in 1a and do not interfere with the “p53 hot
spot” Phe3, Trp7 and Leu10 when the molecule of 1a adopts an
ideal α-helix (Fig. 3b). This design turned out to be success-
ful32d for the non-photoswitchable peptides; therefore, we
used precursor 1a and its homolog 1b to prepare our DAE-
stapled photoswitchable peptides.
To conjugate the diarylethene unit as a staple to the bis-L-
azidoornithine-substituted linear peptide precursors 1a,b, we
synthesized two bis-alkynes 2,3 (Fig. 4).
Combining the precursors 1a,b and 2,3 by a Cu-catalyzed
“click” reaction yielded target peptides 4–7 with slightly
different sizes and flexibilities of the stapling linkers (Fig. 5).
Fig. 2 General design strategies for the photoswitchable PPI modu-
lators considered in this work.
Fig. 3 (a) Structural formulae of the precursors 1a,b used to prepare
the stapled peptides. The amino acid residues discussed in the text are
highlighted. (b) Helical wheel (left) and helical mesh36 (right) represen-
tations of a 1. The (Orn(N3) residues are denoted as “X”, showing the
relative spatial position of the installed DAE-derived staple.
Fig. 4 Bis-alkyne-substituted DAE-derived precursors for peptide
stapling.
Fig. 5 Stapled DAE-containing peptides studied in this work.
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Peptide synthesis
The linear precursors 1a,b were synthesized manually using
standard Fmoc solid-phase chemistry on a low-loaded
(0.33 mmol g−1) Rink amide resin (see ESI† for details). After
cleavage, 1a,b were purified by a preparative HPLC prior to the
“click” reactions. For stapled peptide synthesis we used two-
component “double-click” protocol elaborated before (see ESI†
for details).37 Corresponding linear peptides 1a,b were coupled
with the building blocks 2,3 in a water/tert-butanol
1 : 1 mixture (at 0.1 mM concentration, 0.01 mmol of 1a,b was
used) at room temperature, in the presence of copper sulfate,
sodium ascorbate, and tris(3-hydroxypropyltriazolyl-methyl)
amine during 1–3 days to obtain the stapled peptides 4–7 with
54–70% yield after HPLC purification.
Photochromic behaviour
The absorption spectra of the synthesized peptides are charac-
terized by the features that are typical for DAE derivatives.9,18
Representative examples are illustrated in Fig. 6. Notably, the
long-wavelength maxima of the “open” photoforms of peptides
4 and 6, which contain non-methylated amide bonds flanking
the DAE fragments were shifted bathochromically by ∼40 nm
compared to the corresponding N-Me derivatives 5 and 7
(Fig. 6).
To evaluate the photochromic properties of 4–7, they were
dissolved in degassed 50% water/acetonitrile or in 8 M urea at
a concentration of 0.5 mM, and irradiated with UV light
(254 nm, ∼20 mW cm−2). The progress of the photoisomeriza-
tion reaction was monitored by analytical HPLC. In the water/
acetonitrile mixture, compounds 4–7 showed moderate conver-
sion to the “closed” form, with a 20–30% conversion achieved
after 30–40 min of continuous irradiation. However, in the
urea solution the photoswitching was more efficient, reaching
the photostationary states with 80–90% of the “closed” photo-
form after 10–20 min of irradiation. In this chaotropic environ-
ment the peptides are presumably less structured, which pro-
vides the DAE moiety with a higher population of the antipar-
allel rotamer needed for the photoconversion. We have pre-
viously observed this effect also for the DAE-modified cyclic
β-hairpin peptides.38 No by-products were found when
irradiation was carried out under an argon atmosphere. In
contrast, fast degradation of the peptides was observed in the
presence of oxygen, suggesting the involvement of reactive
oxygen species in this process.
To test the reverse, i.e. the “closed” to “open” transform-
ation, the same solutions were subjected to irradiation gener-
ated by different LED sources. All compounds were converted
to the “open” photoforms quantitatively by irradiation with
green light (λmax = 528 nm, Fig. 7a), also without any detect-
able formation of by-products according to analytical HPLC. In
Fig. 6 Representative absorption spectra of the DAE-stapled peptides.
The spectra were recorded at the concentration of 20 µM in 10 mM
phosphate buffer (pH 7.4) in 10 mm quartz cuvette at ambient
temperature.
Fig. 7 “Closed” to “open” photoconversion of peptides 6 and 7 by light
of different wavelengths: (a) 528 nm; (b) 600 nm; (c) 625 nm, plotted as
a function of light radiant exposure. The experiments were performed at
a concentration of 20 µM in 10 mM phosphate buffer, pH 7.4, in 10 mm
light-path cuvettes at ambient temperature. The conversion was moni-
tored at the absorption maximum for each peptide.
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our experimental set-up, complete photoconversion by this
light source (1.8 mW cm−2 at 4 cm distance to the peptide
solution) was reached for all compounds in ∼16 min. Besides,
we found that appreciable photoconversion into the “open”
forms, especially for the non-methylated analogues 4 and 6,
can be induced by orange (λmax = 600 nm) or even red light
(λmax = 625 nm), under comparable light exposures (Fig. 7b
and c). This is an important feature for the possible future use
of such compounds in vivo, because light with a longer wave-
length penetrates tissues of live organisms more deeply and
without causing damage.39
For the following experiments, all of the peptides 4–7 were
obtained in their pure “open” and “closed” photoforms by pre-
parative HPLC.
The efficiency of binding to MDM2
First, the binding affinity to MDM2 was assessed for peptides
4–7 and compared with that for the pDI. In order to compare
the results with the literature data,40 we used the p53-inter-
acting domain of human MDM2 (MDM26–125) for the assays.
The value of the dissociation constant (Kd) for pDI was deter-
mined using an assay based on direct tryptophan fluo-
rescence quenching. Apparent dissociation constants (Ki) for
4–7 were measured in the presence of pDI as a tracer, using a
similar competition assay.41 The use of both Trp fluo-
rescence-based assays was possible, because the only binding
partner possessing a tryptophan fluorescence was pDI. The
p53 binding domain MDM26–125 contains no Trp residues,
and the Trp fluorescence of 4–7 turned out to be negligible
under the measurement conditions due to strong intra-
molecular quenching by the DAE chromophore. The assay
was sensitive enough, allowing us to perform measurements
at low concentrations of the binding partners (1 µM, see
further details in the ESI†), which was essential to avoid their
aggregation. We found a Kd of 3.0 ± 1.0 nM for pDI; this value
is in agreement with the literature data.32b Our measure-
ments also revealed that all DAE-modified peptides have Ki
values in the picomolar-to-low nanomolar range (Table 1),
comparable with the most powerful known MDM2
antagonists,22a,32b including the known non-photoswitchable
stapled peptides.32d,42
We were also pleased to find that the photoisomers of
each DAE-modified peptide were systematically different: the
binding efficiency was stronger (the Ki lower) for all the
“open” photoforms compared to the corresponding “closed”
photoisomers. In order to confirm the data for our most
efficient inhibitors, we additionally conducted Ki measure-
ments using a fluorescence polarization (FP) competition
assay. A known fluorescent inhibitor, 5′-
TAMRA-RFMDYWEGL-NH2, was used as a tracer; the results
are also listed in Table 1. These results were in agreement
with the data obtained by the Trp fluorescence quenching
assay for the same compounds, and indeed confirmed the
very high efficiency of the binding for the peptides 5–7 in the
“open” photoforms.
Structural characterization
Next, we explored the conformational preferences of 4–7 in
solution by circular dichroism (CD) spectroscopy. To evaluate
the impact of photoisomerization on the secondary structure
in these experiments, we first acquired CD spectra of the light-
sensitive “closed” photoforms kept in darkness. The samples
were then irradiated with visible light (λmax = 550 nm, irradi-
ance ∼20 mW cm−2, 10 min), achieving in situ complete con-
version to the “open” isomers, and CD spectra were measured
again under no light protection. We also acquired the CD spec-
trum of the template peptide pDI for the comparison. The
results are illustrated in Fig. 8 (see ESI† for experimental
details).
We compared the peptide conformations under conditions
close to the binding experiment (10 mM phosphate buffer, pH
7.4, 0.005% Tween 20). We did not detect any isosbestic point
between pDI and 4–7 in the aqueous buffer. Hence, in solu-
tion, equilibrium must exist between more than two confor-
Table 1 Experimental data on binding of 4–7 and their parent peptide
pDI to MDM26–125
Peptide
Ki (Kd)
(nM)
Closed/open
Ki ratio
d
ΔH
(kJ mol−1)
−TΔS
(kJ mol−1)
4 “open” 4.0 ± 0.6a 8.3 −24.6 ± 1.6 −23.3 ± 2
4 “closed” 33.0 ± 3.9a −36.0 ± 1.7 −6.7 ± 2.1
5 “open” 0.8 ± 0.1a 2.5 −33.0 ± 1.2 −18.9 ± 1.5
1.6 ± 0.2c
5 “closed” 2.0 ± 0.3a −48.5 ± 1.9 −1.4 ± 2.3
6 “open” 4.9 ± 0.6a 5.5 −18.6 ± 2.5 −28.7 ± 2.7
5.7 ± 0.3c
6 “closed” 26.8 ± 4.6a −28.6 ± 2.0 −14.6 ± 2.6
7 “open” 1.9 ± 0.2a 3.8 −26.9 ± 1.2 −22.8 ± 1.5
0.4 ± 0.1c
7 “closed” 7.2 ± 1.6a −34.0 ± 2.4 −12.5 ± 3.0
pDI (3.0 ± 1.0b) −53.3 ± 3.7 4.7 ± 4.7
aDetermined by a competitive Trp fluorescence quenching assay.
bDetermined by a direct Trp fluorescence quenching assay.
cDetermined by a fluorescence polarization competition assay. d The
data of the Trp fluorescence quenching assay were used.
Fig. 8 Representative far-UV CD spectra of pDI and the two photo-
forms of peptides 6 and 7 (50 µM peptide solutions in phosphate buffer,
supplemented with 0.005% Tween 20 at 25 °C). Spectra of the “closed”
photoforms were recorded in 1 mm light-path cuvettes, the spectra of
the corresponding “open” photoforms were measured after the in situ
photoisomerization by irradiation with 550 nm light.
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mations of the peptides. Indeed, spectral deconvolution
(Table 2) revealed some non-negligible (20–40%) contributions
from non-helical structures. Overall, however, the helicity
increased upon photoisomerization from the “closed” to the
“open” photoform (from 33–43% to 41–46%), and a decrease
in the non-structured fraction (from 26–29% to 21–26%) was
observed at the same time. These results suggested that 4–7
are more helical than pDI, and that the “open” photoforms are
more structured than the “closed” isomers.
Noticeably, the conformational differences between the
“closed” and “open” isomers did not correlate with the differ-
ences in Ki. Our data suggested, therefore, that the percentage
of α-helix in aqueous solutions is a poor predictor of MDM2
binding for our stapled peptides. This conclusion is further
corroborated by the results from a recent paper by Lane,
Sawyer et al.,44 who studied the impact of helix-perturbing resi-
dues on the affinity of their peptides to MDM2 and also found
no direct correlation.
A possible explanation of the facts described above may be
based on the assumption that both photoforms of the peptides
bind to the target protein partly involving their linkers. The
involvement of linkers of stapled peptides in the binding to
target proteins was reported earlier in the literature.32b,c,45 The
binding of our DAE linkers, irrespective of the photostate,
could contribute to the observed high efficiency of binding,
and at the same time attenuate the role of the “hot spot” resi-
dues and hence the helicity. In order to test this hypothesis,
we carried out additional experimental and computational
studies of the MDM26–125 complexes with one of our best
binding compounds, peptide 5.
First, we obtained crystals of MDM26–125 in complex with
the “open” form of 5, which is suitable for co-crystallisation.
Attempts to crystallise the “closed” form were not successful,
possibly due to residual “open” form peptide forming upon
exposure to ambient light and resulting in a non-homogenous
composition. In the solved structure (PDB ID: 6Y4Q), the crys-
tallographic unit cell has P1 symmetry and contains two
protein and two ligand molecules each, resulting in two 1 : 1
complexes per asymmetric unit. The peptide binds as
expected, forming an α-helix, with the Phe3, Trp7 and Leu10
“hot-spot” residues residing in the known lipophilic pockets
on the protein (Fig. 9a). The linker points outside the binding
pocket on its N-proximal half, whereas the remaining half
forms several interactions with the protein, confirming our
hypothesis that the linker directly contributes to the inter-
action. Edge-to-face π-stacking interactions are observed
between the triazole and thiophene moieties of the linker and
Phe55 of the protein. The triazole ring also forms hydrogen
bonds to a nearby water molecule, which, in turn, forms an
H-bond with Gln59. Unexpectedly, however, the DAE moiety
was observed participating in the crystal packing and forming
contacts with the complex from a neighbouring unit cell
(Fig. 9b).
It is challenging to assert whether a similar binding mode
would be present in solution, as we did not observe other
crystal forms. We can only speculate that the presence of such
Table 2 Conformational analysis based on the CD data.
Concentration-normalized spectra were analysed with the CDSSTR
algorithm,43 using the reference dataset 3. Results are expressed as % of
the conformations in terms of CDSSTR methoda
Peptide αr αD βr βD T U NRMSD
b
4 “open” 27 16 8 7 17 24 0.021
4 “closed” 19 14 12 10 19 26 0.014
5 “open” 28 18 9 7 16 21 0.008
5 “closed” 27 16 11 8 16 25 0.005
6 “open” 27 14 11 9 13 26 0.005
6 “closed” 25 14 8 7 16 29 0.008
7 “open” 30 16 8 7 13 26 0.005
7 “closed” 27 16 8 7 15 27 0.010
1a 33 21 7 6 10 23 0.008
pDI 23 17 12 8 16 24 0.005
a αr – regular α-helix; αD – distorterd α-helix; βr – regular β-strand; βD –
distorted β-strand; T – turns; U – unstructured. bNormalized root
mean square deviation.
Fig. 9 Crystal structure of MDM2 with 5“open” (PDB ID: 6Y4Q). (a) The
binding mode of 5“open” in complex with MDM26–125 as deduced from
X-ray crystallographic model. The peptide and linker are shown in blue;
MDM26–125 surface is depicted in grey. Orange dashed lines represent
π-stacking interactions, black dashed lines are hydrogen bonds; (b) the
linker of the peptide 5 forms contacts with the nearby complex in the
asymmetric unit.
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dimers in the dilute solutions used by us in the Ki measure-
ments is rather improbable.
Next, a computational study was performed in two steps.
The first step was the molecular docking of both photoisomers
of 5 to the MDM26–125 molecule. Conformationally flexible
ligands and a rigid protein were used at this stage. The phar-
macophore model of the protein binding site was derived from
our X-ray data above. We used an algorithm for systematic
docking (SDOCK+) implemented in the QXP docking software,
which was capable of reproducing the ligand conformation
with minimum root mean square deviation (RMSD) in com-
parison to the crystallographic data.46 Complexes with the
“open” and “closed” photoforms of ligand 5 were calculated
separately. The second step consisted of a molecular dynamics
(MD) simulation of the complexes obtained by docking, using
the GROMACS 5.1.3 software tool and a Charmm36 force field
(see ESI† for computational details).47 Each complex was sep-
arately simulated five times, and the results of all simulations
were consistent.
Our MD simulations demonstrated a good stability of the 5/
MDM26–125 complexes within the simulation time (100 ns),
independently as to whether the ligand was in the “open” or in
the “closed” photoform. The essential Trp7, Phe3 and Leu10
residues of the ligands interacted with the corresponding
protein sites in all cases, but surprisingly, this binding mode
slightly changed during the simulation time. In particular,
interaction of Leu10 with its initial binding site was not pre-
served during the entire simulation period. Importantly, the
simulations identified numerous contacts between the sta-
pling linker of peptide 5“open” and the protein (Fig. 10a), con-
firming our hypothesis about an involvement of the linker in
the binding. One end of the linker in the complexes did not
interact with MDM26–125, it pointed away from the binding
pocket. The nearest observed distances between the atoms of
the linker and protein were 6.7 Å and 7.0 Å, for the open and
closed photophorms, respectively. The other end of the linker,
in the case of the 5“open”, interacted with the protein at Lys51
and Phe55 by unstable hydrogen bonds, aromatic stacking of
the DAE with Phe55, and by π-cation interaction with Lys51.
Inspection of the complex with 5 in the “closed” photoform,
however, showed that this structure differed significantly from
the complex with 5“open” (Fig. 10b). The linker in this case
interacted with the protein as well, but the number of contacts
was reduced. Furthermore, the entire DAE moiety pointed
away from the protein surface and did not form any contacts
with the protein. The binding mode of the linkers changed
slightly during the 100 ns simulation, as they left their initial
binding pocket. Still, in both cases the interactions with the
protein mentioned above were stable throughout the whole
simulation period.
Estimation of enthalpy and entropy of binding
It is widely recognized that the thermodynamic signature of
binding is crucial in the recognition event of an active ligand,
and that both enthalpic and entropic control may define the
overall selectivity of binding.48 A growing body of evidence
suggests that PPIs are characterized by a rather complex inter-
play of enthalpy and entropy of the binding event. Peptide
ligands that interfere with PPIs can interact with the target
protein either by enthalpy- or by entropy-driven mechanisms.49
Which mechanism will be dominant depends largely on the
conformational dynamics of the peptide. Even subtle changes
in the rigidity/flexibility balance of their molecular structure
may significantly affect both thermodynamic parameters of
the free binding energy and, consequently, efficiency and
selectivity of the binding process.50 We have thus
suggested11,51 that the two photoisomers of DAE-containing
peptides may differ so prominently in their ability to modulate
PPIs, because they differ fundamentally in their flexibility/
Fig. 10 Snapshots (at 50th ns) of MD simulations of the 5/MDM26–125
complexes: (a) complex with the “open” photoform of 5; (b) complex
with the “closed” photoform of 5. The ligand is shown in grey/blue/red
colours; the protein is drawn in yellow. Amino acid residues of the
protein involved in binding are denoted with the three-letter code.
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rigidity (Fig. 1). The more flexible “open” photoform should
generally facilitate the formation of a particular conformation
that is required for binding. On the other hand, the rigid
“closed” DAE form would rather be expected to destabilize
such specific conformation in the desired structural context.
We have already observed such an effect of the DAE moiety
when incorporated into the backbones of cyclic β-hairpin
peptides and in linear α-helix-DAE-α-helix conjugates. In the
case of the DAE-stapled peptides 4–7, the CD spectra
described above suggested a similar influence of the DAE
photoswitch on the stability of the α-helix, in agreement with
the results of Fujimoto et al.13 In particular, the “open”
photoforms of our peptides in water were more structured in
the peptidic part than the “closed” photoforms (Table 2).
Consequently, the “open” photoforms may not pay an exces-
sive entropic penalty upon binding, as they are pre-organized
for binding and should therefore have better affinities. The
hypothesis about this effect of preorganization is still a
subject of hot debate in the literature,19b,20 however, it has
been experimentally proven in the case of some stapled p53/
MDM2 inhibitors.49
In order to gain insight into the thermodynamic para-
meters of the 4–7/MDM26–125 binding, we performed isother-
mal titration calorimetry (ITC) measurements. The ITC data
could shed light on the relative contributions of enthalpy and
entropy to the overall free energy of binding.52 Unfortunately,
the sensitivity of the method did not allow us to reliably esti-
mate the Kd values at low concentration (<20 μM) of the pep-
tides. For a reliable determination of Kd, the so-called c-value
(c = [MDM26–125]n/Kd, where [MDM2
6–125] is the concentration
of the protein and n is the stoichiometry of the reaction)
should be between 1 and 1000.53 Even at low concentrations,
where aggregation of the binding partners was not observed,
the c-values for our peptides are expected to be much higher
than 1000. The enthalpies of binding, ΔH, however, could be
measured by ITC with sufficient confidence even in such
cases. Combining these ΔH values with the dissociation con-
stants determined by other assays, one can get the corres-
ponding entropies of binding, ΔS, using the well-known
relation ΔG = ΔH − TΔS = −RT × ln(Kd−1), as was demonstrated
on many examples.53,54 Therefore, we decided to fit our ITC
data and the apparent values of Kd from the Trp fluorescence
quenching assay to the single-site binding model to obtain the
corresponding binding entropies.55 The thermodynamic para-
meters of the 4–7/MDM26–125 binding thus obtained are listed
in Table 1. These data, illustrated for clarity in Fig. 11, revealed
a striking difference for the two photoisomeric states: while
the binding of the “closed” forms seems to be enthalpy-driven,
the “open” isomers bind with a substantial contribution of
entropy. The difference is particularly pronounced for peptides
4 and 6, i.e. those compounds for which we had measured the
most significant differences in Ki values between the two
photoforms. It is known that different ligands can have signifi-
cantly different thermodynamic signatures of binding to
MDM2,49 as determined by their conformational landscape.56
In our peptides, the DAE photoswitch seems to provide a
means to control these features in one and the same molecule,
simply by the use of light.
Contribution of conformational dynamics to binding
Although the thermodynamic parameters that we estimated
for the 4–7/MDM26–125 binding seem to indicate that a preor-
ganization of the “open” forms of our molecules can be the
reason of their more favourable binding entropy and binding
energy compared to the corresponding “closed” forms, the
overall picture is not as simple. As was pointed out by several
authors,20,49 there are many examples of seemingly counter-
intuitive deviations from this paradigm. In our case, this
became obvious when we observed no apparent correlation
between the binding affinities on the one hand and the struc-
tural differences between the photoisomers on the other. We
suspected that this may be due to the overall conformational
dynamics of the complexes, which contribute to the binding
entropy and play a significant role in the photoswitching
efficiency of the compounds 4–7.
The conformational dynamics can make the structure–
activity correlations not as straightforward. For example,
binding of some peptide-derived ligands to their protein
targets was shown not to benefit from conformation-stabiliz-
ing stapling57 or rigidification;58 on the contrary, confor-
mationally flexible, less structured ligands may actually have a
higher affinity.59 To compare the conformational dynamics of
the binding partners in our case, we analysed the MD trajec-
tories of MDM26–125 complexes with 5 in the “open” and
“closed” photoforms. Conformational movements of the
ligands and the protein are reflected by their all-atom root
mean square fluctuations (RMSFs), calculated over the entire
simulation period. As can be seen from Fig. 12a, the RMSFs
for 5“open” were higher than for 5“closed” in the simulated 5/
MDM26–125 complexes, which means that 5“open” has much
more conformational freedom. Notably, the 5“open” RMSFs
Fig. 11 Thermodynamics of binding of the peptides 6–9 to MDM26–125.
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exceed those of 5“closed” not only in the area of the linker,
but also in the α-helical peptidic region. In turn, this enhanced
mobility seems to contribute to the more favourable binding
entropy of 5“open”. We further suggest that this may well be a
result of the enhanced molecular flexibility of the DAE moiety
in the “open” configuration, as it lacks the rigidifying bond
between the two thiophene rings (see Fig. 1).
The freedom of conformational motion of a bound ligand
can modulate the overall conformational dynamics of the
protein–ligand complex, which is known to govern the overall
Gibbs energy of the interaction.60 Some insights into the
protein dynamics can also be gained from the MD simulation
results. The RMSF differences for some of the protein atoms in
the complexes 5“open”/MDM26–125 and 5“closed”/MDM26–125
are quite pronounced and depend on the protein region. Some
protein moieties are more mobile (RMSF are larger) in the
complex with 5“open”, but there are also some regions that are
more dynamic in the 5“closed”/MDM26–125 complex (compare
the red and black traces in Fig. 12b). It is also interesting to
compare the RMSF of the ligand-free protein (which we have
simulated separately, green trace in Fig. 12b) and of the
protein in the complexes with 5. The overall changes in the
protein conformational landscape upon complexation of the
ligands are too complex to allow drawing any specific con-
clusions, but it is evident that these changes are significantly
different for the complexes with 5“open” and 5“closed”, corro-
borating the observed Ki difference for the photoisomers.
These findings warrant further studies into the contribution of
conformational dynamics to protein–ligand interactions, and
DAE-modified ligands may indeed represent valuable model
systems in this field.
Conclusions
A “double-click” macrocyclization reaction of the linear precur-
sors 1a,b possessing L-azidoornithine/L-azidolysine residues in
(i, i + 7)-positions with the bis-alkyne DAE-derived linkers 2
and 3 can be used to obtain efficiently photoswitchable pep-
tides, capable of photoregulating PPI inhibition. We demon-
strated here that an up to 8-fold difference in the affinity of the
two photoforms of an MDM2 binding peptide can be achieved
by rational design, with the affinity of one of the photoisomers
being in the picomolar range. Generally, the more active,
“open” photoisomers tend to bind to the protein better due to
a more favourable binding entropy, while the binding of the
“closed” photoisomers is predominantly enthalpy-driven. The
efficiency of photoregulation seems to be affected by a partial
involvement of the linker moiety in the binding. Notably, the
more efficient MDM26–125 binders are those peptide photoi-
somers that are generated by visible light, and both photoi-
somers are perfectly thermally stable. These properties may
boost the further development of DAE-based PPI modulators
as possible drug candidates for photopharmacology.
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